NRX Pharmaceuticals, Inc. Warrant(NRXPW)
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
- Industry (SIC)
- PHARMACEUTICAL PREPARATIONS (2834)
- Exchange
- XNAS
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
| Month | Avg Return | Years of Data |
|---|---|---|
| Jan | -23.06% | 5 |
| Feb | -12.39% | 5 |
| Mar | -29.33% | 5 |
| Apr | -13.59% | 5 |
| May | -8.23% | 6 |
| Jun | -7.71% | 5 |
| Jul | +35.18% | 5 |
| Aug | -2.92% | 5 |
| Sep | -28.81% | 5 |
| Oct | +12.38% | 5 |
| Nov | -5.65% | 5 |
| Dec | +37.99% | 5 |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
Choose Frenzy-Fast™ for quick analysis or Frenzy-Pro™ for comprehensive analysis.
Analysis includes technical indicators, news sentiment, risk assessment, and specific price levels to watch.
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR25 and BF25 from the live options chain. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Enter a ticker to render the implied volatility surface.
- Beta (1Y vs SPY)
- -1.16
- Correlation (SPY)
- -3.7%
- R²
- 0.00
- Ann. Volatility
- 372.2%
- SPY Volatility
- 11.9%
Negative beta - stock moves opposite to market
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SIMPLEX TRADING, LLC Custodian | $175.51K | 92.69% | 2026-03-31 |
| 2 | GROUP ONE TRADING LLC Custodian | $13.85K | 7.31% | 2026-03-31 |
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | SIMPLEX TRADING, LLC Custodian | $1.70K | 66.67% | 2026-03-31 |
| 2 | GROUP ONE TRADING LLC Custodian | $852 | 33.33% | 2026-03-31 |
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-02-17 | Joseph Michael Casper | Chief Operating Officer | Grant (A) | +100,000 opt | — | EDGAR | |
| 2025-09-10 | Jonathan C Javitt | Chairman and Chief Scientist | Grant (A) | +125,000 opt | — | EDGAR | |
| 2025-09-10 | Dennis McBride | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2025-09-10 | Chaim Hurvitz | Director | Grant (A) | +25,000 opt | — | EDGAR | |
| 2025-09-10 | Patrick John Flynn | Director | Grant (A) | +50,000 opt | — | EDGAR | |
| 2025-02-11 | MICHAEL S ABRAMS | Chief Financial Officer | Grant (A) | +50,000 opt | — | EDGAR | |
| 2024-12-18 | Jonathan C Javitt | Chairman and Chief Scientist | Buy (P) | +40,000 | $1.17 | $46.8K | EDGAR |
| 2023-09-11 | Chaim Hurvitz | Director | Buy (P) | +70,000 | $0.29 | $20.1K | EDGAR |
| 2023-09-11 | Aaron Gorovitz | Director | Buy (P) | +35,000 | $0.32 | $11.2K | EDGAR |
| 2023-08-24 | Jonathan C Javitt | Chief Scientist | Buy (P) | +100,000 | $0.33 | $33.0K | EDGAR |
| 2023-08-23 | Jonathan C Javitt | Chief Scientist | Buy (P) | +200,000 | $0.32 | $64.4K | EDGAR |
| 2022-12-19 | Stephen H Willard | CHIEF EXECUTIVE OFFICER | Buy (P) | +50,000 | $1.17 | $58.5K | EDGAR |
| 2022-12-19 | SETH VAN VOORHEES | CHIEF FINANCIAL OFFICER | Buy (P) | +30,000 | $1.10 | $33.0K | EDGAR |
| 2022-12-19 | SETH VAN VOORHEES | CHIEF FINANCIAL OFFICER | Buy (P) | +16,337 | $1.11 | $18.2K | EDGAR |
| 2022-12-09 | Jonathan C Javitt | Director | Sell (S) | −400,000 | $1.00 | -$400.0K | EDGAR |
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | Daniel C. Javitt | 10%+ Owner | 9,634,793 | $25.1K | -$1.35M | 8 | 2022-12-01 |
| 2 | Chaim Hurvitz | Director | 2,006,350 | $5.2K | $1.05M | 5 | 2025-09-10 |
| 3 | BRAC Lending Group LLC | 10%+ Owner | 590,435 | $1.5K | $0 | 2 | 2021-06-04 |
| 4 | RICHARD ACKERMAN | President & CEO | 492,065 | $1.3K | $0 | 1 | 2021-05-25 |
| 5 | Jonathan C Javitt | Chairman and Chief Scientist | 114,634 | $298 | $5.60M | 8 | 2025-09-10 |
| 6 | Aaron Gorovitz | Director | 105,000 | $273 | $11.2K | 3 | 2023-09-11 |
| 7 | Stephen H Willard | CHIEF EXECUTIVE OFFICER | 50,000 | $130 | $58.5K | 1 | 2022-12-19 |
| 8 | Daniel Troy | Director | 43,093 | $112 | $0 | 1 | 2021-06-10 |
| 9 | Patrick John Flynn | Director | 39,459 | $103 | $14.7K | 4 | 2025-09-10 |
| 10 | Alessandra Daigneault | General Counsel & Secretary | 33,715 | $88 | -$442.0K | 2 | 2021-11-02 |
| 11 | Robert Besthof | Interim CEO | 23,710 | $62 | -$470.4K | 3 | 2022-03-10 |
| 12 | Herbert Raymond McMaster | Director | 18,300 | $48 | $0 | 1 | 2021-11-02 |
| 13 | SETH VAN VOORHEES | CHIEF FINANCIAL OFFICER | 18,032 | $47 | $69.4K | 3 | 2022-12-19 |
| 14 | Sharon Glied | Director | 13,168 | $34 | $0 | 2 | 2022-11-22 |
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.